Tissue Diagnostics Global Market Report 2022: Sector to Reach $8.52 Billion by 2029 at a 7.4% CAGR
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Tissue Diagnostics Market by Product Type, Technology, Cancer Type, and End user - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
The tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. The key factors attributing to the large market share of this segment are the repetitive need for consumables and technological advances in developing novel consumables.
For instance, in May 2022, Qiagen N.V. (Netherlands) launched its therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis. It detects all the currently known activating and resistance EGFR mutations.
Based on technology, in 2022, the immunohistochemistry segment is expected to account for the largest share of the market. Immunohistochemistry provides variations between different types of tumors over conventional enzyme staining techniques; thus, the adoption of IHC for conducting immunodiagnostics tests and point-of-care diagnostic tests for tissue diagnostics is high. This contributes to the large market share of this segment.
Based on application, the tissue diagnostics market is segmented into breast cancer, lung cancer, colorectal and gastrointestinal cancer, prostate cancer, lymphatic cancer, and others. In 2022, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high prevalence of breast cancer and the presence of several research and screening programs. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced USD 47.5 million in funding to support breast cancer research during 2021-22.
Based on end user, in 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The rising prevalence of cancer globally and the subsequent high inflow of patients to hospitals and reference laboratories support the large market share of this segment.
Scope of the Report:
Global Tissue Diagnostics Market, by Product Type
Slide Staining Systems
- Global Tissue Diagnostics Market, by Technology
In-situ Hybridization (ISH)
H&E Slide Staining
- Global Tissue Diagnostics Market, by Application
Colorectal and Gastrointestinal Cancer
- Global Tissue Diagnostics Market, by End User
Hospitals and Reference Laboratories
Contract Research Organization
Global Tissue Diagnostics Market, by Geography
Rest of Europe (RoE)
Rest of APAC (RoAPAC)
Middle East & Africa
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Tissue Diagnostics Market, by Product Type
6. Tissue Diagnostics Market, by Technique
7. Tissue Diagnostics Market, by Application
8. Tissue Diagnostics Market, by End User
9. Tissue Diagnostics Market, by Geography
10. Competitive Landscape
11. Company Profiles
F. Hoffmann-La Roche Ltd (Switzerland)
Danaher Corporation (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Abbott Laboratories (U.S.)
Agilent Technologies Inc. (U.S.)
Merck KGaA (Sigma-Aldrich Co. LLC) (Germany)
Sakura Finetek Japan Co. Ltd. (Japan)
Abcam plc (U.K.)
Becton Dickinson and Company (U.S.)
QIAGEN N.V. (Netherlands)
Cell Signaling Technology Inc. (U.S.)
Bio-Genex Laboratories Inc. (U.S.)
Bio SB Inc (U.S.)
3DHISTECH Ltd. (Hungary)
HOLOGIC Inc. (U.S.).
For more information about this report visit https://www.researchandmarkets.com/r/pzyjxa
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900